MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Economic and Financial Impacts of Cancer
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,125 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,125 works in the cohort · of 4,299,418page 10 of 23

Labels cover 7 of 1,125 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,125 of 1,125 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
The financial impact of cancer care on renal cancer patients.
Doreen A. Ezeife, Brendon Josh Morganstein, Steven Yip, Malcolm Ryan, Jennifer Law, Amy Yimin Guan +6 more
2021· article· en· PubMed· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
A Systematic Review of Health Economic Evaluations in Radiation Oncology
Timothy K. Nguyen, Christopher D. Goodman, Gabriel Boldt, A. Warner, David A. Palma, George Rodrigues +4 more
2015· review· en· International Journal of Radiation Oncology*Biology*Physics· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Annie Lemelin, Kosuke Takemura, Devon J. Boyne, Matthew T. Warkentin, Darren R. Brenner, Wookwang Cheun +14 more
2023· article· en· Annals of Oncology· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Targeting the value of targeted therapy
Joseph C. Del Paggio, Richard Sullivan, Christopher M. Booth
2017· editorial· en· Oncotarget· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Arm morbidity and financial difficulty in breast cancer survivors
Sara P. Myers, Alison Laws, Laura S. Dominici, Mirelle Lagendijk, Samantha Grossmith, Elizabeth A. Mittendorf +1 more
2024· article· en· Journal of Cancer Survivorship· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About